1. Home
  2. TR vs FOLD Comparison

TR vs FOLD Comparison

Compare TR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tootsie Roll Industries Inc.

TR

Tootsie Roll Industries Inc.

HOLD

Current Price

$36.37

Market Cap

2.9B

ML Signal

HOLD

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.28

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TR
FOLD
Founded
1896
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
4.4B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
TR
FOLD
Price
$36.37
$14.28
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$27.56
AVG Volume (30 Days)
125.1K
20.1M
Earning Date
02-27-2026
02-18-2026
Dividend Yield
1.00%
N/A
EPS Growth
0.79
N/A
EPS
1.28
N/A
Revenue
$729,620,000.00
$598,704,000.00
Revenue This Year
N/A
$21.49
Revenue Next Year
N/A
$18.42
P/E Ratio
$27.90
N/A
Revenue Growth
0.34
21.28
52 Week Low
$28.67
$5.51
52 Week High
$44.27
$14.36

Technical Indicators

Market Signals
Indicator
TR
FOLD
Relative Strength Index (RSI) 43.64 89.90
Support Level $34.93 $14.21
Resistance Level $38.17 $14.35
Average True Range (ATR) 0.86 0.08
MACD -0.07 -0.01
Stochastic Oscillator 47.37 97.72

Price Performance

Historical Comparison
TR
FOLD

About TR Tootsie Roll Industries Inc.

Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: